News Archives Archive - Page 27 of 58 - Adverum Biotechnologies

Avalanche Biotechnologies, Inc. Reports First Quarter 2015 Financial Results

May 13, 2015

MENLO PARK, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need,...

Avalanche Biotechnologies to Present at Upcoming Scientific Meetings

April 28, 2015

MENLO PARK, Calif., April 28, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need,...

Avalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness

March 25, 2015

Vision Experts Jay and Maureen Neitz Join Company'sScientific Advisory Board Company Launches www.colorvisionawareness.com to Provide More Information for People with Color Blindness MENLO PARK, Calif. and SEATTLE, March 25, 2015 (GLOBE NEWSWIRE) -- Avalanche...

Avalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015

March 18, 2015

MENLO PARK, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies, Inc. Reports Fourth Quarter and Fiscal 2014 Financial Results

March 5, 2015

MENLO PARK, Calif., March 5, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies to Present at Upcoming Investor Conferences

February 25, 2015

MENLO PARK, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock

January 8, 2015

MENLO PARK, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies Announces Proposed Public Offering of Common Stock and Partial Release of Lock-Up Agreements in Connection Therewith

January 5, 2015

MENLO PARK, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies to Present at the 26th Annual Piper Jaffray Healthcare Conference

November 26, 2014

MENLO PARK, Calif., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies to Present at the Jefferies Global Healthcare Conference

November 13, 2014

MENLO PARK, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Archived Press Releases